Structured Abstract
Objective To determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the cause of COVID-19 disease) exposure in pregnancy, compared to non-exposure, is associated with infection-related obstetric morbidity.
Design and setting Throughout Spain, 45 hospitals took part in universal screening of pregnant women going into labour using polymerase-chain-reaction (PCR) for COVID-19 since late March 2020.
Methods The cohort of exposed and unexposed pregnancies was followed up until 6-weeks post-partum. Multivariate logistic regression analysis, adjusting for known confounding variables, determined the adjusted odds ratio (aOR) with 95% confidence intervals (95% CI) of the association of COVID-19 exposure, compared to non-exposure, with infection-related obstetric outcomes.
Main outcome measures Preterm delivery (primary), premature rupture of membranes and neonatal intensive care unit admissions.
Results In the cohort of 1,009 screened pregnancies, 246 were COVID-19 positive. Compared to non-exposure, COVID-19 exposure increased the odds of preterm birth (34 vs 51, 13.8% vs 6.7%, aOR 2.12, 95% CI 1.32–3.36, p = 0.002), premature rupture of membranes at term (39 vs 75, 15.8% vs 9.8%, aOR 1.70, 95% CI 1.11–2.57, p = 0.013) and neonatal intensive care unit admissions (23 vs 18, 9.3% vs 2.4%, aOR 4.62, 95% CI 2.43 – 8.94, p< 0.001).
Conclusion This first prospective cohort study demonstrated that pregnant women infected with SARS- CoV-2 have more infection-related obstetric morbidity. This hypothesis merits evaluation of a causal association in further research.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://osf.io/k82ja/?view_only=61d3773cc12f423b8568ff11acb0fa44
Funding Statement
This study was fully funded with public funds obtained in competitive calls: grant COV20/00020 from the Institute of Health Carlos III and co-financed with FEDER funds.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures were approved by Puerta de Hierro University Hospital (Madrid, Spain) ethics committees (reference number, 55/20). All the 76 hospitals involved in the previously created Emergency Obstetrics Spain Group recognized and adopted the procedures. Written informed consent was obtained, sometimes in a delayed fashion, from the study patients at each centre when possible. The majority of the informed consents were provided verbally depending on local ethics committee regulations and special policies issued for Covid-19 research due to the pandemic situation. All verbal consents were recorded in the patient medical records.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All variables of the data base and logistic regression strategies are available in OSF STROBE checklist for cohort studies have been completed
https://osf.io/k82ja/?view_only=61d3773cc12f423b8568ff11acb0fa44
